News Search Results
Mar 17, 2025, 13:00 ET BioCentriq Rebrands as Made Scientific to Redefine Cell Therapy, Defy Limits, and Deliver Results
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For More Information Contact [email protected]
More news about: Made Scientific, Inc
Mar 17, 2025, 12:12 ET City of Miami Mayor Francis Suarez and JP Global Advisors Founder Jeannette Paulino Host Exclusive Fireside Chat at Anthony Ritossa's 24th Global Family Office Investment Summit
Mayor Suarez explored Miami's five-year vision, which prioritizes safety, low taxes and innovation with the convergence of finance, technology, and biotechnology among the key drivers of economic expansion. Under Mayor Suarez's tenure, the city has attracted companies managing over $12 trillion in assets,
More news about: Ritossa Family Office
Mar 17, 2025, 12:00 ET Micro Bioreactor System Market Booms at 10.7% CAGR - Innovations in Pharma & Biotech Drive Growth | Valuates Reports
this market are Sartorius, Applikon Biotechnology, Pall Corporation, PARR, M2p-labs, INFORS HT and others. The top 5 companies share a market share of about 50% in 2019. Key Companies: SartoriusApplikon BiotechnologyEppendorfPall CorporationParrM2p-labsPBS
More news about: Valuates Reports
Mar 17, 2025, 10:13 ET Theradaptive Welcomes Jeffrey W. Dunn to its Board of Directors
Mr. Dunn brings over three decades of leadership experience in the medical device, biotechnology, and technology sectors. Currently serving as Chairman of the Board at SI-BONE, Inc., a leading musculoskeletal medical device company he co-founded
More news about: Theradaptive
Mar 17, 2025, 09:00 ET Gene Bio Medical and BIDIPHAR Announce Strategic Joint Venture to Revolutionize Global Healthcare
Vietnam, March 17, 2025 /PRNewswire/ - Gene Bio Medical (GBM), a leading Canadian biotechnology company specializing in molecular diagnostics, has signed a Memorandum of Understanding (MOU) with Bình Định Pharmaceutical - Medical Equipment
More news about: Gene Bio Medical
Mar 17, 2025, 09:00 ET Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis
Calif., March 17, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient
More news about: Evommune, Inc
Mar 17, 2025, 08:00 ET Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit
More news about: Anixa Biosciences, Inc.
Mar 17, 2025, 08:00 ET Arthrosi Announces First Patient Dosed in Replicate Pivotal Phase 3 REDUCE 1 Trial of Lead Compound AR882
DIEGO, March 17, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Mar 17, 2025, 07:45 ET ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process
About ChromaTan, Inc.Headquartered in Spring House, PA, ChromaTan is a trusted partner to the biotechnology industry, specializing in biomanufacturing process intensification through its proprietary Biologic Real Moving Bed (BioRMB™) technology. BioRMB™
More news about: Landmark Bio
Mar 17, 2025, 07:00 ET Tract Bio Announces Publication in Gastroenterology Revealing Potential Therapeutic Targets in the Evolution of Esophageal Adenocarcinoma Identified Using stemECHO™ Cloning Platform
BOSTON, March 17, 2025 /PRNewswire/ -- Tract Bio, a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the publication of preclinical research
More news about: Tract Bio
Mar 17, 2025, 06:10 ET iOncologi, Inc. Announces the Appointment of Dr. Mona Flores and Mr. Paolo Fundarò to Its Board of Directors
sciences-focused VC firm investing in early-stage drug development. He was formerly the CEO of Genextra, where he played a key role in guiding biotechnology and medical device companies through growth and commercialization. His financial and operational expertise will be instrumental in shaping iOncologi's
More news about: iOncologi, Inc.
Mar 17, 2025, 06:00 ET Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of
More news about: Chance Pharmaceuticals
Mar 17, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 17, 2025, 05:00 ET Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, today announced it has closed $150
More news about: Latigo Biotherapeutics
Mar 16, 2025, 11:45 ET Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 15, 2025, 06:07 ET Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today presents on its novel SKY-0515 small molecule
More news about: Skyhawk Therapeutics
Mar 14, 2025, 19:42 ET iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors
biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi's capabilities in developing
More news about: iOncologi, Inc.
Mar 14, 2025, 16:21 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 14, 2025, 04:23 ET Accropeutics Secured $12 Million in Series B Plus Financing
March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,
More news about: Accropeutics
Mar 13, 2025, 18:15 ET INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
MEETING, Pa., March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 13, 2025, 16:07 ET Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Mar 13, 2025, 16:05 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Glancy Prongay & Murray LLP
Mar 13, 2025, 16:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 13, 2025, 13:05 ET Multi-Use Bioreactor Market in Pharmaceuticals and Research Institutions to Hit USD 12.26 Billion by 2029, Growing 9.7% Annually | Valuates Reports
infrastructure reinforces the market's long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors. Unlock Insights: View Full Report Now!
More news about: Valuates Reports
Mar 13, 2025, 10:08 ET PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes
www.pranax.com), an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from The University of Texas MD Anderson Cancer Center
More news about: PranaX